12:00 AM
 | 
Jun 23, 2008
 |  BioCentury  |  Emerging Company Profile

Diagnoplex: Simplifying colon screening

The gold standard for colorectal cancer diagnostics is colonoscopy, yet the invasive nature of the test consistently leads to poor compliance among the at-risk population. Diagnoplex S.a.r.l. believes its non-invasive test will not only improve compliance, but also be able to detect colorectal cancer at earlier stages than other non-invasive testing methods, and perform comparably to colonoscopy.

CEO Stavros Therianos noted that most patients perceive colonoscopy to be uncomfortable. “If you take the population at risk worldwide, it’s around 200 million people, and at maximum 20% of the people at risk actually consult for colon cancer screening,” he told BioCentury.

Noninvasive tests performed using feces or blood - such as the fecal occult blood test (FOBT) or a variety of tests that look for gene mutations in samples - do not have to break through this psychological barrier. But Therianos said they lack sensitivity and specificity in the earlier stages of the disease.

“All these tests have some sensitivity and specificity for later...

Read the full 798 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >